Pfenex and Hospira to develop Lucentis biosimilar candidate

Clinical-stage biotechnology firm Pfenex has partnered with Hospira to develop and commercialise PF582, Pfenex's biosimilar candidate to Genentech's Lucentis (ranibizumab injection).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news